Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-6598 · 1 trial · 1 indication
DLT is defined as any of the following toxicities, unless assessed by investigator as due to the underlying disease or extraneous causes: Grade (Gr) 4 nonhematologic toxicity (not laboratory); Gr 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Gr 4 thrombocytopenia of any duration; Gr 3 thrombocytopenia associated with clinically significant bleeding lasting ≥7 days; Gr 4 anemia of any duration; Nonhematologic AE Gr ≥3 in severity, with exceptions; Any Gr 3/4 nonhematologic lab abnormality if it requires clinically significant medical intervention, leads to hospitalization, persists for \>72 hours, or results in certain drug-induced liver injuries, with some exceptions; Gr 3 or 4 febrile neutropenia; \>2 week delay in initiating Cycle 2 due to treatment-related toxicity; Treatment-related toxicity resulting in study treatment discontinuation during Cycle 1 (C1), 1 cycle = 21 days; Missing \>25% of MK-6598 doses due to treatment-related AE during C1; Gr 5 toxicity.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| MK-6598 | EXPERIMENTAL | Participants received MK-6598 daily (QD) between 50-500 mg for up to a total of 35 cycles (up to approximately 24 months). Participants were allowed at the investigator's discretion and after consultation with the Sponsor, to cross over to receive combination treatment of MK-6598 and Pembrolizumab |
| MK-6598 + Pembrolizumab | EXPERIMENTAL | QD between 50-250 mg, plus pembrolizumab 200 mg once every 21-day cycle for up to 35 cycles (up to approximately 24 months). |
| Name | Type | Description |
|---|---|---|
| MK-6598 | DRUG | Oral tablet |
| Pembrolizumab | BIOLOGICAL | Intravenous (IV) infusion |
Inclusion Criteria: * Has a histologically- or cytologically-confirmed advanced/metastatic solid tumor by pathology report and has received, or been intolerant to, all treatment known to confer clinical benefit. * Has measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MK-6598 is an investigational small molecule being studied for the treatment of advanced or metastatic solid tumors. It is being evaluated as a monotherapy and in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors.
MK-6598 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in advanced solid tumors.
MK-6598 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under clinical investigation.
MK-6598 has been studied in a Phase 1 trial with the identifier NCT05594043. This trial evaluated MK-6598 as monotherapy and in combination with pembrolizumab in patients with advanced or metastatic solid tumors. The trial enrolled 39 participants and has been completed.
No, MK-6598 is not the same as pembrolizumab. MK-6598 is a separate investigational small molecule being studied by Merck. Pembrolizumab, also known as MK-3475, is an approved immunotherapy that is being tested in combination with MK-6598 in the clinical trial.